2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol | 328919-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol
• 英文别名: 2-[1,1a(2)-Biphenyl]-3-yl-5-methyl-4-oxazoleethanol；2-[5-methyl-2-(3-phenylphenyl)-1,3-oxazol-4-yl]ethanol
• CAS: 328919-25-1
• 化学式: C₁₈H₁₇NO₂
• 分子量: 279.338
• InChiKey: DHCJKTNHCHRUBF-UHFFFAOYSA-N

物化性质

• 沸点：
  488.9±47.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol 在 吡啶 、 4-二甲氨基吡啶 、 sodium hydroxide 、 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-p-tolyloxy-propionic acid
  参考文献：
  名称：

  Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis

  摘要：

  To understand the species selectivity in a series of a-methyl-a-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.(C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.031
• 作为产物：
  描述：

  [2-(3-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 在 palladium diacetate 、 氢氧化钾 、 硼烷 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇甲醚 为溶剂， 生成 2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol
  参考文献：
  名称：

  Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis

  摘要：

  To understand the species selectivity in a series of a-methyl-a-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.(C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.031

文献信息

• Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040138277A1

  公开（公告）日：2004-07-15

  1 Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

  对PPAR受体进行调节的新型化合物，以及其药用盐、溶剂合物和水合物，制备这些化合物的过程，含有这些化合物或其药用盐、溶剂合物和水合物的药物组合物。
• [EN] BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS<br/>[FR] DERIVES DE BIARYL-OXA(THIA)ZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PPAR
  申请人：LILLY CO ELI

  公开号：WO2001016120A1

  公开（公告）日：2001-03-08

  Compounds represented by Formula (I) wherein n is 2, 3, or 4; V is O or S; W is O, S, or SO2 and at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; are modulators of peroxisome proliferator activated receptors and are useful in the treatment of type II diabetes and of cardiovascular diseases.

  公式（I）所代表的化合物中，其中n为2、3或4；V为O或S；W为O、S或SO2，且至少有一个R5为取代或未取代的芳基或取代或未取代的杂环基；是过氧化物酶体增殖物激活受体的调节剂，并且在治疗2型糖尿病和心血管疾病方面有用。
• [EN] OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE OXAZOLYL-ARYLPROPIONIQUE ET LEUR UTILISATION COMME AGONISTES DES PPAR
  申请人：LILLY CO ELI

  公开号：WO2002016332A1

  公开（公告）日：2002-02-28

  Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

  一种调节PPAR受体的新型化合物，以及其药学上可接受的盐、溶剂化物和水合物，制备该化合物的方法，含有该化合物或其药学上可接受的盐、溶剂化物和水合物的药物组合物。
• Modulators of peroxisome proliferator activated receptors
  申请人：Eli Lilly & Company Lily Corporate Center

  公开号：US20030045558A1

  公开（公告）日：2003-03-06

  The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: 1 In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO 2 ; R 1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R 2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R 3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R 5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R 5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R 6 is H, a C1-C4 alkyl, or an aminoalkyl.

  本发明涉及结构式I所表示的化合物及其药学上可接受的盐、溶剂和水合物，以及制备方法、使用方法和含有结构式I所表示的化合物及其药学上可接受的盐、溶剂和水合物的药物组合物： 在结构式I中，n为2、3或4；V为O或S；W为O、S或SO2；R1为H、C1-C4烷基、苯基或三氟甲基；R2各自独立地为H、C1-C6烷基、芳基-C1-C6烷基、环烷基-C1-C4烷基、芳基、环烷基或与它们所连接的苯基一起形成萘基或1,2,3,4-四氢萘基；R3各自独立地为H、C1-C6烷基、芳基-C1-C6烷基、环烷基-C1-C4烷基、芳基或环烷基；R4各自独立地为H、C1-C4烷基、芳基或苄基；R5各自独立地为H、取代或未取代的芳基或杂环芳基，但至少有一个R5为取代或未取代的芳基或取代或未取代的杂环芳基；R6为H、C1-C4烷基或氨基烷基。
• BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1206457A1

  公开（公告）日：2002-05-22